Back to Search
KEISHAWANA EDWARDS
Behavior Technician
NPI: 1972470565Individual
Specialties, Licenses & Credentials
Behavior TechnicianPrimary
Behavior Technician
Code: 106S00000X
Clinical Trials (3)
3
Linked Trials
0
Recruiting
1
With Results
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
NCT01970410COMPLETEDPHASE4STUDY_DIRECTOR
Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients
NCT01968902COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
NCT02683863COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Research & Publications (20)
The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.
PMID 34950502·Mult Scler J Exp Transl Clin·2021
8-other
Disease-modifying treatments for progressive multiple sclerosis.
PMID 24062415·Mult Scler·2013
6-review
Progressive multiple sclerosis: pathology and pathogenesis.
PMID 23007702·Nat Rev Neurol·2012
6-review
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
PMID 22992073·N Engl J Med·2012
3-trial
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
PMID 22992072·N Engl J Med·2012
3-trial
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
PMID 22591293·N Engl J Med·2012
8-other
Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway.
PMID 22267202·J Pharmacol Exp Ther·2012
4-observational
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells.
PMID 21987655·J Exp Med·2011
7-preclinical
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.
PMID 21354971·Brain·2011
7-preclinical
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.
PMID 21297955·PLoS One·2011
7-preclinical
Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.
PMID 20937940·Arch Neurol·2011
8-other
Pathophysiology of multiple sclerosis and the place of teriflunomide.
PMID 20880295·Acta Neurol Scand·2011
6-review
Anti-JC virus antibodies: implications for PML risk stratification.
PMID 20737510·Ann Neurol·2010
8-other
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
PMID 19339255·Brain·2009
8-other
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
PMID 18987352·Neurology·2009
3-trial
The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease.
PMID 18717629·Antioxid Redox Signal·2009
6-review
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
PMID 16510744·N Engl J Med·2006
3-trial
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
PMID 16230320·Brain·2005
8-other
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).
PMID 12525714·Neurology·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12459 LEWIS ST STE 201
GARDEN GROVE, CA 92840 - Phone
- (800) 249-1266
Quick Facts
- NPI
- 1972470565
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 3
- Publications
- 20
Are you this provider?
Claim Your Profile